MARLBOROUGH, Mass.,
Aug. 31, 2017 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
clinical-stage RNAi company developing innovative therapeutics that
address significant unmet medical needs, announced today that Dr.
Geert Cauwenbergh, RXi's President
and CEO, will present at the 8th Annual Investing for
Cures Forum hosted by Landmark Angels.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Date: Thursday, September 7, 2017
Time:
9:15 a.m. ET
Location:
Club 101, 101 Park Avenue, New York
City, NY
The presentation will be available under the "Investors – Events
and Presentations" section of the Company's website,
www.rxipharma.com, approximately 1 hour following the
presentation.
RXi's Next Generation Therapeutic Platform:
sd-rxRNA®
A successful RNAi therapeutic platform includes stable, specific
and potent RNAi compounds and the ability to deliver these
compounds to the tissue(s) of interest. Scientists at RXi
have developed proprietary compounds in which drug-like properties
are built into the RNAi compound itself. These novel
compounds are termed 'self-delivering' RNAi compounds or sd-rxRNA.
RXI-109, a potent anti-fibrotic agent, was developed based on the
novel chemistry of the sd-rxRNA platform. RXI-109 is designed
to reduce the expression of CTGF, a critical regulator of several
biological pathways involved in fibrosis, including scar formation
in the skin and eye. RXI-109 first entered clinicals trial in
June 2012.
RXi's development pipeline also includes sd-rxRNA compounds for
immunotherapy to treat cancer. Our approach to immunotherapy
builds on well-established methodologies of adoptive cell transfer.
Immune cells, such as T-lymphocytes, are isolated from specific
patients or retrieved from allogeneic immune cell banks, and then
expanded and possibly processed to express tumor-binding receptors.
Our method introduces sd-rxRNA compounds directed against
immunosuppressive targets as a new and important step in
ex-vivo processing of the immune cells. This step eliminates
the expression of immunosuppressive receptors or proteins from the
therapeutic immune cells, making them less sensitive to tumor
resistance mechanisms and thus improving their ability to destroy
the tumor cells.
RXi has recently advanced its immunotherapy pipeline with the
selection of two self-delivering RNAi (sd-rxRNA®) compounds for
preclinical development. For oncology treatments based on adoptive
cell transfer (ACT), sd-rxRNA compounds RXI-762 and RXI-804
suppress the expression of immune checkpoint proteins PD-1 and
TIGIT respectively, which may result in an improved efficacy to the
targeted tumors. This decision triggered the selection of a
manufacturing facility to initiate production of cGMP grade
material, initially for the first of these two compounds (RXI-762).
The latter also supports moving RXI-762 into clinical development
as early as 2018 as part of an ACT therapy.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including self-delivering RNA
(sd-rxRNA®) compounds, that have the ability to highly selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-corporation-selected-to-present-at-the-8th-annual-investing-for-cures-forum-300512033.html
SOURCE RXi Pharmaceuticals Corporation